A Phase 3 study (NCT05907122) investigating the similarity of ABP 206 compared to OPDIVO® (Nivolumab) in subjects with resected melanoma reached primary completion on 2025-03-26. The trial, which enrolled 256 participants, aimed to evaluate pharmacokinetic similarity, efficacy, safety, and immunogenicity.
Background
Nivolumab, marketed as OPDIVO®, is an established immunotherapy used in various cancers, including melanoma. This study focuses on ABP 206, a potential biosimilar, which aims to demonstrate high similarity to the reference product, Nivolumab, in terms of pharmacokinetics, efficacy, safety, and immunogenicity for patients with resected melanoma.
Trial design
The study, identified as NCT05907122, is a Phase 3 trial with an enrollment of 256 subjects. It investigated the similarity of ABP 206 against FDA-licensed nivolumab and EU-authorized nivolumab in subjects diagnosed with melanoma. The primary objective was to assess the pharmacokinetic similarity, along with evaluating efficacy, safety, and immunogenicity profiles between the investigational product and the reference nivolumab.
What this means
The primary completion of this Phase 3 study signifies that data collection for the primary objectives has concluded. The next steps will involve the analysis of the collected data to determine the pharmacokinetic similarity, efficacy, safety, and immunogenicity of ABP 206 compared to Nivolumab. Successful demonstration of biosimilarity could lead to ABP 206 becoming an alternative treatment option for patients with resected melanoma, potentially increasing access and affordability.
Source
The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The study record for NCT05907122, titled 'A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma,' was updated to reflect primary completion on 2025-03-26 on clinicaltrials.gov.